Who makes NKX101 - CAR NK cell therapy?

NKX101 - CAR NK cell therapy is developed by Nkarta, Inc..

What development phase is NKX101 - CAR NK cell therapy in?

NKX101 - CAR NK cell therapy is in Phase 1.

Last reviewed 2026-05-13 · How we verify

NKX101 - CAR NK cell therapy

Nkarta, Inc. · Phase 1 active Biologic

At a glance

Generic name	NKX101 - CAR NK cell therapy
Also known as	Cyclophosphamide, Fludarabine, Cytarabine (ara-C), Decitabine
Sponsor	Nkarta, Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NKX101 - CAR NK cell therapy CI brief — competitive landscape report
NKX101 - CAR NK cell therapy updates RSS · CI watch RSS
Nkarta, Inc. portfolio CI